PTN
Palatin Technologies, Inc.
Biotechnology
Market Cap$10M
5Y Perf.-3.1%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
PTN vs EVAX vs NKTR vs NEON
Revenue, margins, valuation, and 5-year total return — side by side.
EVAX
Evaxion Biotech A/S
Biotechnology
Market Cap$26M
5Y Perf.-98.8%
NKTR
Nektar Therapeutics
Biotechnology
Market Cap$1.69B
5Y Perf.-75.5%
NEON
Neonode Inc.
Hardware, Equipment & Parts
Market Cap$31M
5Y Perf.-76.9%
PTN vs EVAX vs NKTR vs NEON — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PTN | EVAX | NKTR | NEON |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Hardware, Equipment & Parts |
| Market Cap | $10M | $26M | $1.69B | $31M |
| Revenue (TTM) | $9M | $8M | $55M | $2M |
| Net Income (TTM) | $-10M | $-8M | $-164M | $8M |
| Gross Margin | 99.2% | 99.7% | 99.6% | 98.7% |
| Operating Margin | -134.8% | -122.7% | -237.9% | -391.5% |
| Forward P/E | — | — | — | 3.6x |
| Total Debt | $164K | $8M | $149M | $371K |
| Cash & Equiv. | $3M | $23M | $15M | $25M |
PTN vs EVAX vs NKTR vs NEON — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PTN
EVAX
NKTR
NEON
| Stock | Feb 21 | May 26 | Return |
|---|---|---|---|
| Palatin Technologie… (PTN) | 100 | 96.9 | -3.1% |
| Evaxion Biotech A/S (EVAX) | 100 | 1.2 | -98.8% |
| Nektar Therapeutics (NKTR) | 100 | 24.5 | -75.5% |
| Neonode Inc. (NEON) | 100 | 23.1 | -76.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PTN vs EVAX vs NKTR vs NEON
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PTN and NEON are tied at the top with 2 categories each — the right choice depends on your priorities. Neonode Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. EVAX also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
PTN
Palatin Technologies, Inc.
The Income Pick
PTN carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.20
- 40.0% 10Y total return vs NKTR's -59.1%
- Beta 0.20 vs NKTR's 1.85
- +199.9% vs NEON's -83.7%
Best for: income & stability and long-term compounding
EVAX
Evaxion Biotech A/S
The Growth Leader
EVAX is the clearest fit if your priority is growth.
- 125.8% revenue growth vs PTN's -100.0%
Best for: growth
NKTR
Nektar Therapeutics
The Secondary Option
NKTR lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
NEON
Neonode Inc.
The Growth Play
NEON is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth -33.7%, EPS growth 224.4%, 3Y rev CAGR -28.6%
- Lower volatility, beta 0.94, Low D/E 1.5%, current ratio 12.05x
- Beta 0.94, current ratio 12.05x
- 411.9% margin vs NKTR's -297.1%
Best for: growth exposure and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | EVAX | 125.8% revenue growth vs PTN's -100.0% |
| Quality / Margins | NEON | 411.9% margin vs NKTR's -297.1% |
| Stability / Safety | PTN | Beta 0.20 vs NKTR's 1.85 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | PTN | +199.9% vs NEON's -83.7% |
| Efficiency (ROA) | NEON | 37.0% ROA vs NKTR's -62.8%, ROIC -46.0% vs -57.2% |
PTN vs EVAX vs NKTR vs NEON — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2022
Segment breakdown not available.
FY 2025
FY 2025
PTN vs EVAX vs NKTR vs NEON — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPTNLAGGINGNKTR
Who Leads Where
EVAX leads in 1 of 6 categories
NEON leads 1 • PTN leads 1 • NKTR leads 0 • 2 tied
Explore the data ↓NKTRNektar Therapeutics
0leads
NEONNeonode Inc.
1leads
EVAXEvaxion Biotech A/S
1leads
PTNPalatin Technologies,…
1leads
6 Total Categories
CATEGORYLEADERvs EVAXvs NEONMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
EVAX4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NEON6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
PTN5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
EVAX leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NKTR is the larger business by revenue, generating $55M annually — 26.8x NEON's $2M. NEON is the more profitable business, keeping 4.1% of every revenue dollar as net income compared to NKTR's -3.0%. On growth, NEON holds the edge at -20.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | PTNPalatin Technolog… | EVAXEvaxion Biotech A… | NKTRNektar Therapeuti… | NEONNeonode Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $9M | $8M | $55M | $2M |
| EBITDAEarnings before interest/tax | -$12M | -$4M | -$130M | -$8M |
| Net IncomeAfter-tax profit | -$10M | -$8M | -$164M | $8M |
| Free Cash FlowCash after capex | -$16M | -$7M | -$209M | -$10M |
| Gross MarginGross profit ÷ Revenue | +99.2% | +99.7% | +99.6% | +98.7% |
| Operating MarginEBIT ÷ Revenue | -134.8% | -122.7% | -2.4% | -3.9% |
| Net MarginNet income ÷ Revenue | -107.4% | -102.4% | -3.0% | +4.1% |
| FCF MarginFCF ÷ Revenue | -177.2% | -88.2% | -3.8% | -5.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -81.9% | -25.3% | -20.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -19.7% | +73.8% | -4.5% | -25.9% |
EVAX leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — EVAX and NKTR and NEON each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | PTNPalatin Technolog… | EVAXEvaxion Biotech A… | NKTRNektar Therapeuti… | NEONNeonode Inc. |
|---|---|---|---|---|
| Market CapShares × price | $10M | $26M | $1.7B | $31M |
| Enterprise ValueMkt cap + debt − cash | $8M | $10M | $1.8B | $6M |
| Trailing P/EPrice ÷ TTM EPS | -0.59x | -3.36x | -8.57x | 3.57x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 3.40x | 30.64x | 14.81x |
| Price / BookPrice ÷ Book value/share | — | 1.53x | 15.66x | 1.24x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Evenly matched — EVAX and NKTR and NEON each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
NEON leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
NEON delivers a 43.2% return on equity — every $100 of shareholder capital generates $43 in annual profit, vs $-4 for NKTR. NEON carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to NKTR's 1.66x. On the Piotroski fundamental quality scale (0–9), NEON scores 5/9 vs NKTR's 2/9, reflecting solid financial health.
| Metric | PTNPalatin Technolog… | EVAXEvaxion Biotech A… | NKTRNektar Therapeuti… | NEONNeonode Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -84.0% | -61.6% | -4.0% | +43.2% |
| ROA (TTM)Return on assets | -53.7% | -29.2% | -62.8% | +37.0% |
| ROICReturn on invested capital | — | -3.0% | -57.2% | -46.0% |
| ROCEReturn on capital employed | — | -57.4% | -55.7% | -38.9% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 | 2 | 5 |
| Debt / EquityFinancial leverage | — | 0.44x | 1.66x | 0.02x |
| Net DebtTotal debt minus cash | -$2M | -$16M | $134M | -$25M |
| Cash & Equiv.Liquid assets | $3M | $23M | $15M | $25M |
| Total DebtShort + long-term debt | $163,781 | $8M | $149M | $371,000 |
| Interest CoverageEBIT ÷ Interest expense | -1244.69x | -10.54x | -4.74x | — |
NEON leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
PTN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PTN five years ago would be worth $13,500 today (with dividends reinvested), compared to $123 for EVAX. Over the past 12 months, PTN leads with a +19985.0% total return vs NEON's -83.7%. The 3-year compound annual growth rate (CAGR) favors PTN at 103.0% vs EVAX's -62.0% — a key indicator of consistent wealth creation.
| Metric | PTNPalatin Technolog… | EVAXEvaxion Biotech A… | NKTRNektar Therapeuti… | NEONNeonode Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +17.8% | -13.6% | +92.0% | 0.0% |
| 1-Year ReturnPast 12 months | +19985.0% | +175.0% | +818.2% | -83.7% |
| 3-Year ReturnCumulative with dividends | +736.3% | -94.5% | +621.8% | -74.8% |
| 5-Year ReturnCumulative with dividends | +35.0% | -98.8% | -72.3% | -78.3% |
| 10-Year ReturnCumulative with dividends | +40.0% | -99.2% | -59.1% | -91.1% |
| CAGR (3Y)Annualised 3-year return | +103.0% | -62.0% | +93.3% | -36.9% |
PTN leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PTN and NKTR each lead in 1 of 2 comparable metrics.
Risk & Volatility
PTN is the less volatile stock with a 0.20 beta — it tends to amplify market swings less than NKTR's 1.85 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NKTR currently trades 76.5% from its 52-week high vs NEON's 6.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PTNPalatin Technolog… | EVAXEvaxion Biotech A… | NKTRNektar Therapeuti… | NEONNeonode Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.20x | 1.29x | 1.85x | 0.94x |
| 52-Week HighHighest price in past year | $31.00 | $12.15 | $109.00 | $29.90 |
| 52-Week LowLowest price in past year | $0.04 | $1.43 | $7.99 | $1.27 |
| % of 52W HighCurrent price vs 52-week peak | +61.0% | +33.5% | +76.5% | +6.1% |
| RSI (14)Momentum oscillator 0–100 | 42.3 | 56.5 | 53.4 | 62.4 |
| Avg Volume (50D)Average daily shares traded | 15K | 32K | 991K | 103K |
Evenly matched — PTN and NKTR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | PTNPalatin Technolog… | EVAXEvaxion Biotech A… | NKTRNektar Therapeuti… | NEONNeonode Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | — |
| Price TargetConsensus 12-month target | — | — | $132.83 | — |
| # AnalystsCovering analysts | — | — | 33 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
EVAX leads in 1 of 6 categories (Income & Cash Flow). NEON leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallPalatin Technologies, Inc. (PTN)Leads 1 of 6 categories
Loading custom metrics...
PTN vs EVAX vs NKTR vs NEON: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is PTN or EVAX or NKTR or NEON a better buy right now?
For growth investors, Evaxion Biotech A/S (EVAX) is the stronger pick with 125.
8% revenue growth year-over-year, versus -100. 0% for Palatin Technologies, Inc. (PTN). Neonode Inc. (NEON) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate Nektar Therapeutics (NKTR) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PTN or EVAX or NKTR or NEON?
Over the past 5 years, Palatin Technologies, Inc.
(PTN) delivered a total return of +35. 0%, compared to -98. 8% for Evaxion Biotech A/S (EVAX). Over 10 years, the gap is even starker: PTN returned +40. 0% versus EVAX's -99. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PTN or EVAX or NKTR or NEON?
By beta (market sensitivity over 5 years), Palatin Technologies, Inc.
(PTN) is the lower-risk stock at 0. 20β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 813% more volatile than PTN relative to the S&P 500. On balance sheet safety, Neonode Inc. (NEON) carries a lower debt/equity ratio of 2% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.
04Which is growing faster — PTN or EVAX or NKTR or NEON?
By revenue growth (latest reported year), Evaxion Biotech A/S (EVAX) is pulling ahead at 125.
8% versus -100. 0% for Palatin Technologies, Inc. (PTN). On earnings-per-share growth, the picture is similar: Neonode Inc. grew EPS 224. 4% year-over-year, compared to -1491. 6% for Palatin Technologies, Inc.. Over a 3-year CAGR, NKTR leads at -15. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PTN or EVAX or NKTR or NEON?
Neonode Inc.
(NEON) is the more profitable company, earning 411. 9% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 411. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EVAX leads at -122. 7% versus -391. 5% for NEON. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PTN or EVAX or NKTR or NEON?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PTN or EVAX or NKTR or NEON better for a retirement portfolio?
For long-horizon retirement investors, Palatin Technologies, Inc.
(PTN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 20)). Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PTN: +40. 0%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PTN and EVAX and NKTR and NEON?
These companies operate in different sectors (PTN (Healthcare) and EVAX (Healthcare) and NKTR (Healthcare) and NEON (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: PTN is a small-cap quality compounder stock; EVAX is a small-cap high-growth stock; NKTR is a small-cap quality compounder stock; NEON is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(PTN: -100.0% · EVAX: -81.9%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.